Literature DB >> 6580616

Latent tissue plasminogen activator produced by human endothelial cells in culture: evidence for an enzyme-inhibitor complex.

E G Levin.   

Abstract

Conditioned medium from cultures of human umbilical vein endothelial cells was analyzed for the presence of tissue plasminogen activator (tPA) and urokinase. Immunoprecipitation studies using metabolically labeled conditioned medium and anti-tPA IgG revealed a single band on autoradiographs corresponding to a Mr of 100,000. No bands were observed after immunoprecipitation with anti-urokinase IgG. The Mr 100,000 tPA was found to be inactive and did not bind to fibrin clots. However, exposure of this tPA to 1% NaDodSO4 resulted in the appearance of plasminogen activator activity with no apparent change in its Mr. Treatment with 10 mM diisopropylfluorophosphate prior to NaDodSO4 activation did not inhibit the NaDodSO4-induced appearance of plasminogen activator activity, indicating that the active site was not available for diisopropylfluorophosphate binding. The possibility that the properties of this Mr 100,000 tPA reflected a tPA-inhibitor complex was examined. Attempts to dissociate such a complex by denaturation, reduction, or extremes of temperature were not successful. However, after treatment of conditioned medium with 1 M hydroxylamine in the presence of 0.1% NaDodSO4, the Mr of the anti-tPA immunoprecipitable material declined by 40,000 to Mr 60,000, a Mr consistent with that of other human tPAs. Hydroxylamine has been shown previously to dissociate covalently coupled serine protease-inhibitor complexes. Furthermore, incubation of purified human melanoma cell tPA with conditioned medium resulted in an increase in its Mr by 40,000 with a concomitant decline in tPA activity. The data suggest that the latent tPA present in the conditioned medium of endothelial cells is composed of a Mr 60,000 tPA associated with an inhibitor.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6580616      PMCID: PMC390074          DOI: 10.1073/pnas.80.22.6804

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  28 in total

1.  Purification and characterization of human vascular plasminogen activator derived from blood vessel perfusates.

Authors:  B R Binder; J Spragg; K F Austen
Journal:  J Biol Chem       Date:  1979-03-25       Impact factor: 5.157

2.  Cleavage at Asn-Gly bonds with hydroxylamine.

Authors:  P Bornstein; G Balian
Journal:  Methods Enzymol       Date:  1977       Impact factor: 1.600

3.  Evidence for an ester linkage between the labile binding site of C3b and receptive surfaces.

Authors:  S K Law; N A Lichtenberg; R P Levine
Journal:  J Immunol       Date:  1979-09       Impact factor: 5.422

4.  The peptide chains of human plasmin. Mechanism of activation of human plasminogen to plasmin.

Authors:  K C Robbins; L Summaria; B Hsieh; R J Shah
Journal:  J Biol Chem       Date:  1967-05-25       Impact factor: 5.157

5.  Interaction of human alpha-1-antitrypsin with porcine trypsin.

Authors:  A B Cohen; D Geczy; H L James
Journal:  Biochemistry       Date:  1978-02-07       Impact factor: 3.162

6.  Crystal structure of the complex of porcine trypsin with soybean trypsin inhibitor (Kunitz) at 2.6-A resolution.

Authors:  R M Sweet; H T Wright; J Janin; C H Chothia; D M Blow
Journal:  Biochemistry       Date:  1974-09-24       Impact factor: 3.162

7.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

8.  Plasminogen: purification from human plasma by affinity chromatography.

Authors:  D G Deutsch; E T Mertz
Journal:  Science       Date:  1970-12-04       Impact factor: 47.728

9.  Factors influencing endothelial cell proliferation in vitro.

Authors:  R T Wall; L A Harker; L J Quadracci; G E Striker
Journal:  J Cell Physiol       Date:  1978-08       Impact factor: 6.384

10.  Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril.

Authors:  P J Fraker; J C Speck
Journal:  Biochem Biophys Res Commun       Date:  1978-02-28       Impact factor: 3.575

View more
  56 in total

1.  Transforming growth factor-ßs as modulators of pericellular proteolytic events.

Authors:  J Keski-Oja; J Lohi; M Laiho
Journal:  Cytotechnology       Date:  1989-12       Impact factor: 2.058

2.  Rapid neural regulation of muscle urokinase-like plasminogen activator as defined by nerve crush.

Authors:  D Hantaï; J S Rao; B W Festoff
Journal:  Proc Natl Acad Sci U S A       Date:  1990-04       Impact factor: 11.205

3.  Impact of plasminogen on an in vitro wound healing model based on a perfusion cell culture system.

Authors:  Moyuru Hayashi; Yuichi Matsuzaki; Motoyuki Shimonaka
Journal:  Mol Cell Biochem       Date:  2008-11-01       Impact factor: 3.396

4.  Immunologic relationship between platelet membrane glycoprotein GPIIb/IIIa and cell surface molecules expressed by a variety of cells.

Authors:  E F Plow; J C Loftus; E G Levin; D S Fair; D Dixon; J Forsyth; M H Ginsberg
Journal:  Proc Natl Acad Sci U S A       Date:  1986-08       Impact factor: 11.205

5.  Human endothelial cell line, ECV304, produces pro-urokinase.

Authors:  K Takahashi; Y Sawasaki
Journal:  In Vitro Cell Dev Biol       Date:  1991-10

6.  New in vivo model to assess venous endothelial cell functions. Effect of defibrotide.

Authors:  T Di Perri; F Laghi Pasini; C Frigerio; P L Capecchi; G L Messa; M Franchi; F Landini; A Burresi; A Ghezzi; L Ceccatelli
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

7.  Filovirus-induced endothelial leakage triggered by infected monocytes/macrophages.

Authors:  H Feldmann; H Bugany; F Mahner; H D Klenk; D Drenckhahn; H J Schnittler
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

Review 8.  Current issues in thrombosis prevention with antiplatelet drugs.

Authors:  G de Gaetano; C Cerletti; E Dejana; J Vermylen
Journal:  Drugs       Date:  1986-06       Impact factor: 9.546

9.  Molecular cloning and preliminary characterization of a novel cytoplasmic antigen recognized by myasthenia gravis sera.

Authors:  T Gordon; B Grove; J C Loftus; T O'Toole; R McMillan; J Lindstrom; M H Ginsberg
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

10.  Cell-free synthesis of enzymically active tissue-type plasminogen activator. Protein folding determines the extent of N-linked glycosylation.

Authors:  N J Bulleid; R S Bassel-Duby; R B Freedman; J F Sambrook; M J Gething
Journal:  Biochem J       Date:  1992-08-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.